Enter Title

 

Journal of Breast Imaging CME-CE Article
Volume 2, Issue 4, July 2020

Title of Activity: Rare Cancer on the Rise: An Educational Review of Breast Implant-associated Anaplastic Large Cell Lymphoma

Date(s) of Activity: July 15, 2020 – July 15, 2023

View CME Article         Access July JBI CME

Educational/Learning Objectives

After completing this activity, the participant should be better able to:

  1. Recognize the appropriate clinical scenarios when the diagnosis of BIA-ALA should be considered.
  2. Identify the appropriate radiologic and pathologic work-up of patients with suspected BIA-ALCL.
  3. Describe the imaging findings associated with BIA-ALCL across different imaging modalities.

Accreditation Information

Physician Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American College of Radiology and Society of Breast Imaging. The American College of Radiology is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement:
The American College of Radiology designates this journal-based activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Radiologic Technologists Accreditation Statement:
The American College of Radiology is approved by the American Registry of Radiologic Technologists (ARRT) as a Recognized Continuing Education Evaluation Mechanism (RCEEM) to sponsor and/or review Continuing Medical Educational programs for Radiologic Technologists and Radiation Therapists.

Radiologic Technologists Credit Designation Statement:
The American College of Radiology designates this educational activity as meeting the criteria for up to 1 Category A credit hour of the ARRT.

Instructions to Receive Credit:
In order to successfully complete the activity, participants must complete an activity evaluation and claim credit commensurate with their participation in the activity.

Contact Information:
For information about the accreditation of this program, please contact the ACR at info@acr.org.

Disclosure of Conflicts of Interest
The ACR Disclosure Policy: In compliance with ACCME requirements and guidelines, the ACR has developed a policy for disclosure and review of potential conflicts of interest, and a method for resolution if a conflict does exist. The ACR maintains a tradition of scientific integrity and objectivity in its educational activities. In order to preserve these values and ensure its educational activities are independent and free of commercial bias, all individuals, including planners, presenters, moderators and evaluators, participating in an ACR educational activity, or an activity jointly provided by the ACR must disclose all relevant financial relationships with any commercial interest.

The following planners and managers have no financial relationships to disclose:
Ana Lourenco, MD; Natalie Ward, Alexis LaCount

The following planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/partner have with commercial interests related to the content of this CME activity:
Jennifer Harvey, MD: Shareholder, Volpara Solutions

The following faculty members have no financial relationships to disclose:
Maria Mitry, MD; Julie Sogani, MD; Elizabeth Sutton, MD; Priyadarshini Kumar, MD; Azadeh Elmi, MD; Sejal Patel, MD; Katherine Gallagher, MD; Brittany Dashevsky, MD; Victoria Mango, MD

The following faculty members reported the following financial relationships or relationships to products or devices they or their spouse/partner have with commercial interests related to the content of this CME activity: Steven Horwitz, MD - Consultant: ADC Therapeutics; ASTEX; C4 Therapeutics; Celgene; Janssen; Kura Oncology; Kyowa Hakko Kirin; Myeloid Therapeutics; Seattle Genetics; Takeda; Verastem. Research Grants: ADC Therapeutics; Aileron; Celgene; Diichi Sankyo; Forty Seven, Inc; Kyowa Hakko Kirin; Millennium/Takeda; Seattle Genetics; Verastem; Portola Pharmaceuticals; Trillium Therapeutics